title: Carcinoid crisis induced by receptor radionuclide therapy with 90Y-DOTATOC in a case of liver metastases from bronchial neuroendocrine tumor (atypical carcinoid).
abstract: SS receptors are overexpressed in many tumors, mainly of neuroendocrine origin, thus enabling the treatment with SS analogs. The clinical experience of receptor radionuclide therapy with the new analog [90Y-DOTA0-Tyr3 ]-octreotide [90Y-DOTATOC] has been developed over the last decade and is gaining a pivotal role in the therapeutic workout of these tumors. It is well known that some procedures performed in diagnostic and therapeutic management of endocrine tumors, such as agobiopsy and hepatic chemoembolization, can be associated with the occurrence of symptoms related to the release of vasoactive amines and/or hormonal peptides from tumor cell lysis. This is the first report of a severe carcinoid crisis developed after receptor radionuclide therapy with 90Y-DOTATOC administered in a patient affected by liver metastases from bronchial neuroendocrine tumor (atypical carcinoid). Despite protection with H1 receptor antagonists, octreotide and corticosteroids, few days after the therapy the patient complained of persistent flushing of the face and upper trunk, severe labial and periocular oedema, diarrhoea and loss of appetite. These symptoms increased and required new hospitalisation. The patient received iv infusion of octreotide associated with H1 and H2 receptor antagonists and corticosteroid therapy, which induced symptom remission within few days. The case here reported confirms that radionuclide therapy is highly effective in determining early rupture of metastatic tissue and also suggests that pre-medication should be implemented before the radiopeptide administration associated with a close monitoring of the patient in the following days.
authors.affiliation: Biomedical and Surgery Science Department, University of Verona, Verona, Italy. mariavittoria.davi@azosp.ur.it
authors.forename: M V
authors.initials: MV
authors.lastname: Davì
authors.forename: L
authors.initials: L
authors.lastname: Bodei
authors.forename: G
authors.initials: G
authors.lastname: Francia
authors.forename: M
authors.initials: M
authors.lastname: Bartolomei
authors.forename: C
authors.initials: C
authors.lastname: Oliani
authors.forename: L
authors.initials: L
authors.lastname: Scilanga
authors.forename: D
authors.initials: D
authors.lastname: Reghellin
authors.forename: M
authors.initials: M
authors.lastname: Falconi
authors.forename: G
authors.initials: G
authors.lastname: Paganelli
authors.forename: V
authors.initials: V
authors.lastname: Lo Cascio
authors.forename: M
authors.initials: M
authors.lastname: Ferdeghini
mesh_terms: D000368:Aged; D001859:Bone Neoplasms / Q000556:secondary; D001984:Bronchial Neoplasms / Q000188:drug therapy / Q000473:pathology* / Q000532:radiotherapy; D002276:Carcinoid Tumor / Q000188:drug therapy / Q000532:radiotherapy; D006801:Humans; D008113:Liver Neoplasms / Q000188:drug therapy / Q000532:radiotherapy / Q000556:secondary*; D008297:Male; D008303:Malignant Carcinoid Syndrome / Q000139:chemically induced*; D015282:Octreotide / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000627:therapeutic use; D015021:Yttrium Radioisotopes / Q000009:adverse effects
chemical_list: D015021:Yttrium Radioisotopes; C496730:90Y-octreotide, DOTA-Tyr(3)-; D015282:Octreotide